Database for
Therapeutic Antibodies
Therapeutic Antibodies
| Entry ID | 2126 |
| INN | Zalutumumab |
| Status | Terminated |
| Drug code(s) | HuMAX-EGFR, mAb 2F8 |
| Brand name | None |
| mAb sequence source | mAb human |
| General Molecular Category | Naked monospecific |
| Format, general category | Full length Ab |
| Format details | None |
| Isotype (Fc) | IgG1 |
| Light chain isotype | kappa |
| Linker | None |
| Ave. DAR | None |
| Conjugated/fused moiety | None |
| Discovery method/technology | Transgenic mouse (GenPharm/Medarex/BMS transgenic mouse platform) |
| Target(s) | EGFR |
| Indications of clinical studies | Head and neck cancer, non-small cell lung cancer, colorectal cancer |
| Primary therapeutic area | Cancer |
| Most advanced stage of development (global) | Terminated at Phase 3 |
| Status | Inactive |
| Start of clinical phase (IND filing or first Phase 1) | June 27, 2003 |
| Start of Phase 2 | |
| Start of Phase 3 | September 15, 2006 |
| Date BLA/NDA submitted to FDA | |
| Year of first approval (global) | None |
| Date of first US approval | |
| INN, US product name | None |
| US or EU approved indications | None |
| Company | Genmab |
| Licensee/Partner | None |
| Comments about company or candidate | Fast track |
| Full address of company | Copenhagen, Denmark Europe Denmark https://www.genmab.com/ |
None
| Anticipated events | None |
| Factor(s) contributing to discontinuation | None |